Synthesis and biological evaluation of furan-1,3,4-oxadiazole as antitubercular, antibacterial, and antioxidant agents.

Asha Ganesh Suryawanshi, Chandni Pathak, Pratik Khona, Milind Janrao Umekar, Uma Dhiraj Kabra

Abstract read

In one paragraph

Article in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Asha Ganesh SuryawanshiDepartment of Pharmaceutical Chemistry, Shri. D. D. Vispute College of Pharmacy and Research Centre, Navi Mumbai, India.

Chandni PathakDepartment of Pharmaceutical Chemistry, Parul Institute of Pharmacy, Faculty of Pharmacy, Parul University, Vadodara, India.

Pratik KhonaDepartment of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, India.

Milind Janrao UmekarDepartment of Pharmaceutics, Smt. Kishoritai Bhoyar College of Pharmacy, Nagpur, India.

Uma Dhiraj KabraDepartment of Pharmaceutical Chemistry, Parul Institute of Pharmacy, Faculty of Pharmacy, Parul University, Vadodara, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimWith the emergence of extensively drug-resistant (XDR) and multidrug-resistant (MDR), tuberculosis (TB) continues to be a major global health concern. This study aims to synthesize and evaluate a new series of furan-1,3,4-oxadiazole hybrids for their multitarget pharmacological potential, including antitubercular, antibacterial, and antioxidant activities. MATERIALS AND

methodsA one-pot cyclization approach was used to synthesize furan-1,3,4-oxadiazole derivatives. Structural characterization was performed using IR, NMR, MS, and elemental analyses. Antitubercular activity was evaluated against Mycobacterium tuberculosis H RESULTS AND DISCUSSION: Among the synthesized compounds,

Indexed as

Anti-Bacterial AgentsAntioxidantsAntitubercular AgentsFuransOxadiazolesBiphenyl CompoundsEscherichia coliMicrobial Sensitivity TestsMolecular Docking SimulationMolecular StructureMycobacterium tuberculosisStaphylococcus aureusStructure-Activity Relationship1,3,4-oxadiazoleAnti-Bacterial AgentsAntioxidantsAntitubercular AgentsBiphenyl CompoundsfuranFuransOxadiazolesantibacterial agentsantioxidant activityantitubercular activityFuran-1,3,4-oxadiazoleInhA enzymemolecular dockingmultitarget

Identifiers

PMID41099073

DOI10.1080/17568919.2025.2570972

PMCPMC12582119

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.